|
See related Leukeran film-coated tab information |
|
|
|
Manufacturer |
Aspen Pharmacare |
|
Distributor |
Hong Kong: Primal |
|
Contents |
Chlorambucil |
|
Indications |
Hodgkin's disease. Certain forms of non-Hodgkin's lymphoma. Chronic lymphocytic leukaemia, Waldenstrom's macroglobulinaemia, advanced ovarian adenocarcinoma, breast cancer in a proportion of patients. |
|
Dosage |
Hodgkin's disease Monotherapy: 0.2 mg/kg/day for 4-8 wk. Non-Hodgkin's lymphoma Monotherapy: 0.1-0.2 mg/kg/day for 4-8 wk initially. Chronic lymphocytic leukaemia 0.15 mg/kg/day until the total leucocyte count has fallen to 10,000/microlitre. Treatment may be resumed 4 wk after the end of the 1st course & continued at 0.1 mg/kg/day. Waldenstrom's macroglobulinaemia Starting dose: 6-12 mg daily until leucopenia occurs; followed by 2-8 mg daily indefinitely. Ovarian carcinoma Monotherapy: 0.2 mg/kg/day for 4-6 wk, Maintenance course: 0.2 mg/kg/day for 2-4 wk w/ 2-6 wk intervals between each course. Advanced breast cancer Monotherapy 0.2 mg/kg/day for 6 wk. Combination therapy w/ prednisolone, methotrexate or 5-fluorouracil 5-7.5 mg/m2/day. |
|
Administration |
Should be taken on an empty stomach (Take on an empty stomach. Ensure adequate hydration. Swallow whole, do not chew/crush.). |
|
Contraindications |
Pregnancy (1st trimester) & lactation. |
|
Special Precautions |
Immunisation using a live organism vaccine has the potential to cause infection in immunocompromised host. Monitor blood counts closely; should not be given to patients who have recently undergone radiotoxic or chemotherapy. In lymphocytic infiltration of bone marrow, daily dose should not >0.1 mg/kg body wt. Renal or hepatic impairment. Childn w/ nephrotic syndrome, patients prescribed high pulse dosing regimens & patients w/ history of seizure disorder. Acute secondary haematologic malignancies. Ensure adequate contraceptive precautions. |
|
Adverse Drug Reactions |
Acute secondary haematologic malignancies esp leukaemia & myelodysplastic syndrome; leucopenia, neutropenia, thrombocytopenia, pancytopenia, bone marrow suppression, anaemia; seizures in childn w/ nephrotic syndrome; nausea, vomiting, diarrhoea, oral ulceration; rash. Rarely, irreversible bone marrow failure, allergic reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis, seizures, movement disorders, peripheral neuropathy, interstitial pulmonary fibrosis, interstitial pneumonia, hepatotoxicity, jaundice, sterile cystitis, drug fever.
View ADR Monitoring Form |
|
Drug Interactions |
Live organism vaccines, phenylbutazone.
View more drug interactions with Leukeran |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
ATC Classification |
L01AA02 - chlorambucil ; Belongs to the class of alkylating agents, nitrogen mustard analogues. Used in the treatment of cancer. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Leukeran film-coated tablet |
|
|
|
Manufacturer: |
Aspen Pharmacare |
|
Distributor: |
Hong Kong: Primal |
|
|
|
|
